Gsk (GSK) FCF Margin (2009 - 2026)

Gsk (GSK) has 18 years of FCF Margin data on file, last reported at 27.31% in Q3 2026.

• For the quarter ending Q3 2026, FCF Margin changed N/A year-over-year to 27.31%; the trailing twelve-month figure through Sep 2026 stood at 19.46% (changed N/A YoY), and the FY2025 full-year result was 27.82%, up 248.0% from the prior year.
• FCF Margin was 27.31% for Q3 2026 at Gsk, down from 35.89% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 35.89% in Q2 2026 to a low of 4.11% in Q1 2023.
• A 5-year average of 22.35% and a median of 20.68% in 2022 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin soared 2305 bps in 2022 and sank 2925 bps in 2023, its largest moves.
• Gsk's FCF Margin stood at 32.19% in 2022, then tumbled by 58 bps to 13.37% in 2023, then jumped by 41 bps to 18.88% in 2024, then plunged by 38 bps to 11.68% in 2025, then jumped by 134 bps to 27.31% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 27.31% in Q3 2026, 35.89% in Q2 2026, and 17.85% in Q1 2026.